{"schema_version":"1.0","type":"article","title":"從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.md","lang":"zh-Hant","date":"2026-06-05","publish_at":"2026-06-05T10:30:00+08:00","updated_at":"2026-06-05","category":"商業分析系列","topic":"臨床與 CMC","tags":["Ruxolitinib","JAK 抑制劑","外用藥","皮膚遞送","Incyte","安成生技","CMC"],"summary":"外用 JAK 抑制劑的核心不是單純抑制 JAK，而是分子能否穿過皮膚、留在局部、降低全身暴露，並在適應症與製劑設計上建立差異化。","key_points":[],"facts":[],"sections":["01｜外用 JAK 抑制劑的真正難點，不是抑制 JAK，而是「皮膚遞送」","02｜Ruxolitinib cream 為什麼能成功？因為它天生適合內外兼用","03｜Delgocitinib 的成功，則來自更精準的皮膚科分子設計","04｜後來者第一條路：做「內外兼用」分子，但門檻很高","05｜第二條路：直接放棄口服，專門為外用設計","06｜第三條路：把已知口服分子改造成外用前藥","07｜第四條路：直接把口服 JAK 抑制劑做成外用，但最考驗製劑能力","08｜外用 JAK 抑制劑真正的價值，是填補類固醇與口服 JAK 之間的空白","09｜後來者該怎麼布局？先問這個分子離外用有多遠","10｜台灣可以怎麼看？安成生技是最直接的外用 JAK 樣本","結語｜外用 JAK 抑制劑的競爭，不是誰先想到 JAK，而是誰最懂皮膚遞送"],"references":[],"images":[{"alt":"外用 JAK 抑制劑的勝負不只在靶點，而在皮膚穿透、局部濃度與全身暴露的平衡。","url":"https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-01.webp"},{"alt":"Ruxolitinib、delgocitinib 與前藥策略代表外用 JAK 抑制劑的不同開發路徑。","url":"https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-02.png"},{"alt":"台灣公司若切入外用 JAK 賽道，關鍵是特定適應症定位、臨床驗證與國際授權故事。","url":"https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-05）。從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？。https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-05-topical-jak-inhibitor-skin-delivery-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}